$BBIO Income Statement | Understand Stock

$BBIO

$68.15 -$0.41 (0.6%) Close

$BBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues, net
License Revenue
Net product revenue
License and services revenue
Royalty revenue
Total revenues, net

Operating costs and expenses:
Cost of license revenue
Cost of products sold
Cost of license revenue and products sold
Cost of revenues
Net product revenue
Cost of license, services, and royalty revenue
Total cost of revenues
Research and development
Selling, general and administrative
Restructuring, impairment, and related charges
Total operating costs and expenses

Loss from operations
Other income (expense), net:
Interest income
Interest expense
Noncash interest expense on deferred royalty obligations
Gain on deconsolidation of subsidiaries
Loss on extinguishments of debt
Net loss from equity method investments
Gain from sale of priority review voucher, net
Other income, net
Total other income (expense), net
Loss before income taxes
Provision for income taxes
Net loss
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests
Net loss attributable to common stockholders of BridgeBio
Net loss per share attributable to common stockholders of BridgeBio, basic and diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted
Net loss per share attributable to common stockholders of BridgeBio, basic (in dollars per share)
Net loss per share attributable to common stockholders of BridgeBio, diluted (in dollars per share)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic (in shares)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted (in shares)

Comments